

Is Acetaminophen/Butalbital (Fioricet) still in shortage in 2026? Get the latest update on availability, pricing, and what you can do as a patient.
If you've been struggling to fill your Acetaminophen/Butalbital prescription — the headache medication many people know as Fioricet — you're not imagining the problem. Butalbital-containing medications have experienced intermittent supply disruptions since 2020, and patients across the country continue to face challenges in 2026.
In this article, we'll give you the latest update on the Acetaminophen/Butalbital shortage, explain what's driving it, tell you what it costs right now, and share practical steps you can take to get your medication.
As of early 2026, Acetaminophen/Butalbital continues to experience intermittent availability issues. While it's not on the FDA's official drug shortage list at all times, many patients report difficulty finding it at their local pharmacies — particularly at large chain pharmacies like CVS, Walgreens, and Rite Aid.
The situation varies by region. Some areas of the country have better supply than others, and availability can change from week to week. The shortage is best described as "rolling" — the medication comes and goes from pharmacy shelves unpredictably.
Several factors continue to drive the supply issues:
Butalbital is a barbiturate, and the DEA sets annual limits on how much can be manufactured in the United States. Even though Acetaminophen/Butalbital/Caffeine (without codeine) is not a federally controlled substance, the raw material butalbital is regulated. When production quotas don't keep pace with demand, shortages result.
The original brand-name product, Fioricet, has been discontinued. Patients now rely entirely on generic versions, which are made by a handful of manufacturers including Teva, Amneal, and Hikma. If even one manufacturer has a production issue, the impact on supply can be significant.
Ongoing raw material sourcing challenges and production bottlenecks continue to affect pharmaceutical manufacturing broadly, and barbiturate products are especially vulnerable due to the additional regulatory requirements. For a deeper explanation, see our article on why Acetaminophen/Butalbital is so hard to find.
Cost is another concern for patients, especially those paying out of pocket. Here's what you can expect:
If cost is a barrier, check out our full guide on how to save money on Acetaminophen/Butalbital, including coupons, discount cards, and patient assistance programs.
While no new formulations of Acetaminophen/Butalbital have been released recently, patients do have more tools available to help them find and afford their medication:
Here are the most effective strategies for locating your medication right now:
For a complete walkthrough, read our guide on how to find Acetaminophen/Butalbital in stock near you.
If you've exhausted your options and still can't locate Acetaminophen/Butalbital, talk to your doctor about temporary alternatives. Several medications can help with tension headaches and migraines, including Triptans, NSAIDs, and Excedrin. Read our full comparison in alternatives to Acetaminophen/Butalbital.
The Acetaminophen/Butalbital shortage is an ongoing challenge in 2026, driven by DEA manufacturing quotas, a limited number of generic producers, and persistent supply chain issues. While the situation has improved compared to its worst points, many patients still face difficulty filling their prescriptions.
Stay proactive: use Medfinder to check availability, explore independent pharmacies, and keep your doctor informed about any difficulty you're having. You can also learn about the medication itself — what it is, its side effects, and drug interactions to watch for.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.